Business Context and Reporting Period
This Form 8-K is a current report filed by LabStyle Innovations Corp. on September 6, 2013, regarding events occurring on August 30, 2013. The filing details amendments to the employment agreement of Erez Raphael, who was appointed President and Chief Executive Officer on August 11, 2013. Note: The request metadata references "Dariohealth Corp.", but the filing text explicitly identifies the registrant as "LabStyle Innovations Corp."
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the execution of Amendment No. 2 to the Personal Employment Agreement with CEO Erez Raphael. Key terms include:
- Salary: Monthly base salary set at NIS 44,000.
- Equity Grant: A one-time grant of 300,000 stock options under the 2012 Equity Incentive Plan.
- Exercise Price: Equal to the closing price of the Company's common stock on August 29, 2013.
- Vesting Schedule: 50% vested immediately; the remaining 50% vests on August 30, 2014.
- Severance: In the event of termination at will, the CEO is entitled to 6 months of base salary plus severance pursuant to Israeli law. Termination for Cause limits entitlement to statutory severance only.
Guidance, Outlook, and Risks
The filing includes a standard cautionary note regarding forward-looking statements. It warns that actual results may differ materially from expectations due to factors including executive negotiations and performance. The Company explicitly states it undertakes no obligation to update forward-looking statements except as required by law. No specific financial guidance or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the correct registrant name (LabStyle Innovations Corp. vs. Dariohealth Corp.) to ensure data relevance.
- Confirm the closing stock price on August 29, 2013, to calculate the exercise price of the 300,000 options granted.
- Review the attached Exhibits 10.1, 10.2, and 10.3 for the full text of the employment agreement and amendments.
- Assess the impact of the NIS 44,000 monthly salary and option grant on the Company's future cash burn and dilution.